# US 2021/0060161 A1 · Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060161 A1
- Document ID: US20210060161A1
- Status: Published application
- Kind: A1
- Application number: 17/088,220
- Filed: 2020-11-03
- Published: 2021-03-04
- Earliest claimed: 2015-04-30
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Bruce Allen BACH; Florian VOGL
- Web page: https://patentgrep.com/patent/US20210060161A1

## CPC

- A61K 33/243: Platinum; Compounds thereof
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 14/475: Growth factors; Growth regulators
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 33/57545: of the ovaries
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and compositions for treating ovarian cancer in a human patient with ascites by administering a therapeutically effective amount of an Ang2 inhibitor in combination with a taxane.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method for treating recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in a human patient with ascites by administering (a) 80 mg/m2 of paclitaxel, via i.v., QW (3 weeks on/1 week off); and (b) 10 mg/kg 2XCon4(C), via i.v., QW (every week).

### Claim 13

A method for treating recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in a human patient with ascites by administering (a) 80 mg/m2 of paclitaxel, via i.v., QW (3 weeks on/1 week off); and (b) 3 mg/kg 2XCon4(C), via i.v., QW (every week).

### Claim 14

A pharmaceutical composition comprising (a) paclitaxel in an amount suitable for administering to a patient 80 mg/m2, via i.v., QW (3 weeks on/1 week off); and (b) 2XCon4(C) in an amount suitable for administering to a patient 10 mg/kg, via i.v., QW (every week).

### Claim 15

A pharmaceutical composition comprising (a) paclitaxel in an amount suitable for administering to a patient 80 mg/m2, via i.v., QW (3 weeks on/1 week off); and (b) 2XCon4(C) in an amount suitable for administering to a patient 3 mg/kg, via i.v., QW (every week).
